Furthermore, recent clinical studies have demonstrated the remarkable potency of cytotoxic T‐cell‐based therapies targeting cancer antigens, and with this in mind we have developed T‐cells engineered with chimeric antigen receptors (CARs) that target CLEC14A on the tumour vasculature. Here, CLEC14A is linked to neoplasm.